Expression and localization of FGFR family in squamous cell carcinoma of head and neck

Abstract

Abstract: PURPOSE: To investigate the expression and localization of FGFR family in squamous cell carcinoma of head and neck (SCCHN) cell lines. METHODS: Total protein was extracted from 10 SCCHN cell lines and the expression of FGFR was detected by Western blot. The localization of FGFR was further demonstrated by immunofluorescence staining in SCC25 and HN4 cell lines. Gray value was measured by Image J. GraphPad Prism 5.01 software package was used for data processing and analysis. RESULTS: FGFR1 expression was detected in 6/10 cell lines and FGFR2, 3, 4 was detectable in all cell lines. The expression of FGFR1, 2, 4 was mainly in the nucleus and cytoplasm while FGFR3 was predominantly localized in cytoplasm. CONCLUSIONS: FGFR shows co-expression in SCCHN cell lines, which may be associated with the tumorigenesis and development of SCCHN.

Key words: Fibroblast growth factor receptors, Squamous cell carcinoma, Head and neck

CLC Number:

R739.8

SHI Chao-ji, ZHOU Rong, HAN Yong, TAO Wen-jie, SUN Shu-yang, ZHANG Zhi-yuan. Expression and localization of FGFR family in squamous cell carcinoma of head and neck[J]. Shanghai Journal of Stomatology, 2016, 25(5): 517-521.

References

[1] Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer[J]. Nat Rev Cancer, 2010, 10(2): 116-129.
[2] Dieci MV, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives [J]. Cancer Discov, 2013, 3(3): 264-279.
[3] Grose R, Dickson C. Fibroblast growth factor signaling in tumorigenesis[J]. Cytokine Growth Factor Rev, 2005, 16(2): 179-186.
[4] Haddad RI, Shin DM. Recent advances in head and neck cancer [J]. N Engl J Med, 2008, 359(11): 1143-1154.
[5] Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer [J]. Clin Cancer Res, 2012, 18(7): 1855-1862.
[6] Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes [J]. Nature, 2007, 446(7132): 153-158.
[7] Hagel M, Miduturu C, Sheets M, et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway[J]. Cancer Discov, 2015, 5(4): 424-437.
[8] Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family[J]. Cancer Res, 2012, 72(8): 2045-2056.
[9] Vairaktaris E, Ragos V, Yapijakis C, et al. FGFR-2 and -3 play an important role in initial stages of oral oncogenesis [J]. Anticancer Res, 2006, 26(6B): 4217-4221.
[10] Nguyen PT, Tsunematsu T, Yanagisawa S, et al. The FGFR1 inhibitor PD173074 induces mesenchymal-epithelial transition through the transcription factor AP-1[J]. Br J Cancer, 2013, 109(8): 2248-2258.
[11] Zhang Y, Hiraishi Y, Wang H, et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas [J]. Int J Cancer, 2005, 117(1): 166-168.
[12] Kim HS, Lee SE, Bae YS, et al. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma[J]. Oncotarget, 2015, 6(4): 2562-2572.
[13] Göke F, Bode M, Franzen A, et al. Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck[J]. Mod Pathol, 2013, 26(10): 1298-1306.
[14] Ipenburg NA, Koole K, Liem KS, et al. Fibroblast growth factor receptor family members as prognostic biomarkers in head and heck squamous cell carcinoma: A systematic review [J]. Target Oncol, 2016, 11(1): 17-27.
[15] Dutra RL, de Carvalho MB, Dos Santos M, et al. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx [J]. PLoS One, 2012, 7(11): e50747.
[16] Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma [J]. Int J Cancer, 2004, 111(2): 213-217.
[17] Murase H, Inokuchi M, Takagi Y, et al. Prognostic significance of the co-overexpression of fibroblast growth factor receptors 1, 2 and 4 in gastric cancer [J]. Mol Clin Oncol, 2014, 2(4): 509-517.